[1] 杨焕. 新药上市前临床试验安全性数据的分析与评价[J]. 中国临床药理学杂志, 2009, 25(5):464-466,470. [2] 郭韶洁, 赵秀丽, 周辉. 临床试验中不良事件管理的问题及探讨[C]// 中国药理学会药物临床试验专业委员会学术研讨会. 2013. [3] FDA.About the Center for Drug Evaluation and Research. [EB/OL].(2018-03-19)[2018-07-11].https://www.fda.gov/aboutfda/centers-offices/officeofmedicalproductsandtobacco/cder/ucm184426.htm. [4] 王涛,王丹,董铎,等.美国药物警戒体系浅析及对我国的启示[J].医药导报,2017,36(4):361-365. [5] Mckenzie R, Fried M W, Sallie R, et al.Hepatic failure and lactic acidosis due to fialuridine(FIAU), an investigational nucleoside analogue for chronic hepatitis B[J]. New England Journal of Medicine, 1995, 333(17):1099-1105. [6] 汤仲明, 沈克温. 从新药Fialuridine临床试验发生死亡获得的教训[J]. 国外医学.药学分册, 1994,(4):239-241. [7] United States Government Publishing Office (GPO). Adverse experience reporting requirements for human drug and licensed biological products; proposed rule[EB/OL].(1994-10-27)[2018-07-12].https://www.govinfo.gov/content/pkg/FR-1994-10-27/html/94-26483.htm. [8] United States Government Publishing Office(GPO). Expedited safety reporting requirements for human drug and biological products; final rule[EB/OL].(1997-10-07)[2018-07-12].https://www.govinfo.gov/content/pkg/FR-1997-10-07/pdf/97-26255.pdf. [9] United States Government Publishing Office (GPO). Safety reporting requirements for human drug and biological products; proposed rule[EB/OL].(2003-03-14)[2018-07-12].https://www.govinfo.gov/content/pkg/FR-2003-03-14/pdf/03-5204.pdf. [10] FDA. Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans[EB/OL]. (2010-09-29)[2018-07-11]. https://www.govinfo.gov/content/pkg/FR-2010-09-29/pdf/2010-24296.pdf. [11] FDA. Safety Reporting Requirements for INDs and BA/BE Studies[EB/OL]. (2012-12)[2018-08-03].https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM227351.pdf. [12] Kelly W K, Halabi S.Reporing of Adverse Event[M]. America:Springer Publishing Company, 2018,141-149. [13] Goldman S A .Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns:[J]. Drug Safety, 2016, 39(10):895-901. [14] Jarow J P, Casak S, Chuk M, et al.The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative[J]. Clinical Cancer Research, 2016, 22(9):2111-2113. [15] Clinical Trials Transformation Initiative. CTTI IND Safety Advancement Project[EB/OL]. (2015-09-20)[2018-08-08].https://www.ctti-clinicaltrials.org/sites/www.ctti-clinicaltrials.org/files/INDsafety-MeetingSummary.pdf [16] Perez R, Archdeacon P, Roach N, et al.Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials[J]. Clinical Trials, 2017, 14(3):225-233. [17] 温宝书. 药品审评制度改革工作情况介绍[Z].北京. 2018. [18] Insight数据库. 现实和解读:CDE 首席科学家何如意[新药临床试验的风险控制异常重要][EB/OL]. (2018-07-10)[2018-08-03].https://mp.weixin.qq.com/s/BPVb1hOhUX2vQAl3yMXTaw. [19] 徐波,王彦. 药物临床试验期间药物安全监控体系的中外比较分析[J].中国新药杂志,2009,18(14):1291-1293. [20] CFDA. 关于征求《药物临床试验质量管理规范》修订稿意见的通知[EB/OL].(2015-02-06)[2018-07-12]. http://samr.cfda.gov.cn/WS01/CL0778/113991.html. [21] CFDA. 总局关于适用国际人用药品注册技术协调会二级指导原则的公告(2018年第10号)[EB/OL].(2018-01-25)[2018-08-08]. http://samr.cfda.gov.cn/WS01/CL0087/223345.html [22] CDE. 关于发布《药物临床试验期间安全性数据快速报告的快速报告标准程序》的通知[EB/OL]. (2018-04-27)[2018-08-08].http://www.cde.org.cn/news.do?id=314449&method=viewInfoCommon. [23] CDE. 关于发布《E2B(R2)安全性消息处理和个例安全性报告技术规范》的通知[EB/OL]. (2018-07-30)[2018-08-09].http://www.cde.org.cn/news.do?method=viewInfoCommon&id=314635. [24] DIA. 从生产企业角度如何改善临床试验中的安全性报告[EB/OL]. (2018-06-07)[2018-07-11].https://mp.weixin.qq.com/s/86XN2FCB28S2OwUlyQi5Pg. [25] Khozin S, Chuk M, Kim T, et al.Regulatory watch: Evaluating the potential for digital submission of expedited premarket safety reports to the FDA[J]. Nature Reviews Drug Discovery, 2016, 15(10):670. [26] 药智网. CFDA又出大动作,药审中心新增四大部门并调整两大核心部门职责任务[EB/OL]. (2018-01-04)[2018-08-16].https://news.pharmacodia.com/web/newinfo/information_8a2d983760-a18e480160bb89b7540aba.html. |